Our Patents

Biocept’s proprietary technologies are protected by multiple patents issued in the US, EU, China, and other territories around the world. Our microfluidic channels are differentiated from other microfluidic channels used for CTC capture based on their unique geometry, particularly the arrangement of posts within the flow channel. The posts are chemically derivatized to enable capture of antibody-tagged CTCs, and are positioned to disrupt streamline or laminar flow of cells through the microfluidic channel to assure they come in contact with the posts for capture. Because the capture area of the microfluidic channel is sealed on one side with a glass cover slip, immunocytochemical and cytogenetic staining and analysis can occur within our microfluidic channel.

Biocept’s proprietary method of enriching the cells that we capture in our micro-fluidic device also helps differentiate our company’s offering. Our antibody capture cocktail, which includes antibodies to a number of tumor-associated antigens from cancer cells of both epithelial and mesenchymal phenotype, as well as cancer stem cells, is the subject of U.S. patent applications and foreign equivalents. In addition to the sets of specific antigens targeted by the cocktail, the application covers the binding of the antibodies to the target CTCs in solution, which we have shown greatly improves the capture efficiency because of superior binding kinetics and the lack of spatial constraints imposed by attachment of the antibodies to a solid surface.

Finally, our blood collection tubes, which contain reagents designed to prevent clumping of blood cells and CTCs that could clog the microfluidic channels and disrupt our assays, are the subject of an issued U.S. Patent. These reagents also provide stability to the sample for shipping and transport, enabling blood samples to be shipped at ambient temperature from a collection site anywhere in the United States, and even outside the United States, to our laboratory in San Diego, California, and perform well in our assays for up to 96 hours after collection. DNA has been shown to be stable and accessible in cells under these conditions, and preliminary work suggests the same may be true for ctDNA, with more research required.

Our proprietary intellectual property enables Biocept to develop and commercialize its technologies and testing services in a differentiated and sustainable manner. The development effort around these proprietary assets aims to increase the adoption of blood-based liquid biopsies to test for biomarkers associated with cancer, and to help inform physicians and their patients when making treatment decisions.

Through our CLIA-certified and CAP-accredited clinical laboratory, we provide diagnostic testing and clinical services that utilize our proprietary technology and trade secrets. In particular, we maintain trade secrets with respect to specimen accessioning, sample preparation, and certain aspects of cytogenetic analysis. All of our trade secrets are kept in confidence and we take steps to ensure that our confidential information is not disseminated, including the use of non-disclosure agreements and confidentiality agreements.


Get answers to commonly asked questions about Biocept’s liquid biopsies.

Learn More